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SUMMARY
Salbutamol-induced cardiac complications are well-established. Herein, we describe a case of a 24-year 
female who was admitted to the emergency department because of a suicide attempt with salbutamol 
(76 mg). Salbutamol abuse induced the development of supraventricular tachycardia and ventricular fibril-
lation. Regular sinus rhythm was restored with defibrillation. The hypokalemic patient who stayed in the 
intensive care unit was discharged after 48 hours of hospitalization.
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CASE REPORT
Introduction
Short-acting β-agonists are used in the management of in-
termittent asthma or chronic obstructive pulmonary disease 
(COPD) exacerbation.[1] Salbutamol shortens both the sinus 
cycle length and sinus node recovery time. In addition, it inc-
reases atrioventricular (AV) nodal conduction and reduces 
the AV nodal refractory time as well as myocardial refractori-
ness.[2] Over the past 40 years, it has been well-documented 
that β adrenergic agonists are associated with several car-
diovascular adverse effects including ischemia, myocardial 
depression, atrial fibrillation (AF), ventricular arrhythmia, 
fatal myocardial band necrosis, and sudden cardiac death.[3]
In this article, we report a 24- year-old female case of suicide 
attempt with salbutamol, which caused ventricular fibrillation 
(VF) in the light of β adrenergic agonist-related side effects.
Case Report
A 24-year-old female case was admitted to the emergency 
department by her relatives due to a suicide attempt with 
salbutamol 76 mg (Ventolin 4 mgx19) four hours post at-
tempt. The patient history revealed no known chronic di-
sease. Upon admission, the patient had mild anxiety with 
a normal overall status and a Glasgow Coma Scale score of 
15. Her arterial blood pressure was 110/60 mmHg, while 
her pulse rate, respiratory rate, and SPO2 was 126 bpm, and 
18 min, 96%, respectively. The patient’s heart sounds were 
rhythmic and tachycardic. Pulmonary auscultation revealed 
no rales or rhonchi and systemic examination indicated no 
pathology. The patient was monitored and an intravenous 
(I.V.) route was restored. Nasogastric decompression was 
performed and activated charcoal (50 g) was administered. 
Baseline electrocardiography (ECG) showed sinus tachycar-
dia. Blood samples were collected for biochemistry tests 
and 0.9% NaCl was infused. Supraventricular tachycardia 
(SVT) developed at 30 minutes (Figure 1). A metoprolol tar-
tarate-5 mg I.V. push was initiated to the patient without 
a history of bronchospasm. The patient was unresponsive 
to β blocker therapy and lost consciousness and developed 
ventricular fibrillation (Figure 2). Biphasic defibrillator at 
200 Joules was used to restore regular heart rhythm. Spon-
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taneous circulation was returned. The patient was in sinus 
rhythm following defibrillation. Biochemistry test results 
on admission were as follows: glucose 230 mg/dL, blood 
urea nitrogen 23.5 mg/dL, creatinine 0.74 mg/dL, asparta-
te aminotransferase 19 U/L, alanine amino transaminase 
20 U/L, amylase 62 U/L, lipase 27 U/L, total bilirubin 0.24 
mg/dL, sodium 139 mmol/L, potassium 2.7 mmol/L, chlo-
rine 107 mmol/L, calcium 9.25 mg/dL, prothrombin time 
11.7 sec, partial thromboplastin time 21.3 sec, international 
normalized ratio 1.05, white blood cells 12.76x103, hemog-
lobin: 12 g/dL, hematocrit: 37.2 RU, platelets 304.000, pH 
7.38, HCO3std 21.6 mmol/L, k+ 2.3 mmol/L lactate 3 mg/
dL, glucose 231 mg/dL, osmolarity 281 mOsm/kg. The hypo-
kalemic patient was administered potassium infusion and 
hospitalized in the intensive care unit (ICU) for 48 hours. No 
malignant arrhythmia was observed during hospitalization. 
The patient followed in intensive care unit and discharged 
with the psychiatric consultation.
Discussion
In recent years, the incidence of suicide has been increasing 
worldwide. Infact, suicide is more prevalent among girls and 
young adults than males. Consistent with this, the incidence 
of suicide is 3.53/100 in men and 2.31/100 in women with ra-
tes in young adults (aged 15 to 24 years) of 4.58/100 in male 
individuals and 5.22/100 in female individuals according to 
the Turkish Statistical Institute (TurkStat).[4] kose et al.[5] also 
reported that women have a higher rate of suicide than men 
and the most commonly used method was drug or toxic 
agent use. In addition, some authors reported that the most 
frequently preferred agents for suicide attempt were anal-
gesics followed by antidepressants, antipsychotics, and car-
diovascular medications.[6] Similarly, our case was a female 
adult and admitted to the emergency service with suicide 
attempt with salbutamol.
Case-control studies showed that β-2 adrenergic agonists 
increased the risk of myocardial infarction (MI), congestive 
heart failure (CHF), cardiac arrest, and sudden cardiac death 
at varying degrees (odds ratio [OR] 1.3 to 3.4).[7,8] Single dose 
β-2 adrenergic agonist produced an increased heart rate by 
9.12 bpm (confidence interval [CI] 95%, 5.32 to 12.92) com-
pared to placebo. The cardiovascular side effects including 
major ones such as increased risk of sinus tachycardia (risk 
ratio [RR] 3.06; 95% CI; 1.7 to 5.5), ventricular tachycardia, AF, 
syncope, CHF, and sudden cardiac death were also increa-
sed with a β-2 adrenergic agonist than placebo (RR 2.54%; 
95% CI; 0.18 to 0.54). The risk of major cardiovascular side 
effects was estimated as 1.61 (95%, CI 0.76 to 3.42), however; 
it did not reach statistical significance. In another study, β-2 
adrenergic agonist was associated with ventricular and atrial 
ectopic heart beats and prolonged Q Tc interval.
[8] Further-
more, sinus tachycardia and tachyarrhythmias were defined 
in several case reports.[9] In our case, we observed sinus tach-
ycardia on admission and SVT followed by VF development. 
Fortunately, the patient responded to defibrillation.
In another study, single dose β-2 adrenergic agonist produ-
ced 0.36 mmol/L decrease in blood potassium level (95% CI, 
0.18 to 0.54).[7] Hyperglycemia and hypotension were also 
among the side effects of the treatment. Additionally, hypo-
kalemia was associated with increased risk of ventricular 
tachycardia and VF in susceptible patients.[10] Similarly, our 
case developed hypokalemia and hyperglycemia. After SVT, 
ventricular fibrillation developed during treatment. This can 
most likely be attributed to the hypokalemia of the patient. 
We believe that the increased adrenergic activity and hypo-
kalemia combined facilitated the ventricular fibrillation.
Conclusion
In conclusion, β-2 adrenergic agonists at therapeutic doses 
may cause cardiac and metabolic side effects. Such effects 
may be considerably evident in patients with drug abuse. 
The patients with salbutamol abuse should be under me-
dical supervision for the management of electrolyte distur-
bances and malignant arrhythmias.
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Figure 1. Electrocardiography showing supraventricular tachycar-
dia.
Figure 2. Electrocardiography showing ventricular fibrillation.
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